Last reviewed · How we verify

Libexin® — Competitive Intelligence Brief

Libexin® (Libexin®) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-narcotic antitussive. Area: Respiratory / Pulmonology.

phase 3 Non-narcotic antitussive Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Libexin® (Libexin®) — Dompé Farmaceutici S.p.A. Libexin is a non-narcotic antitussive agent that suppresses cough by acting as a local anesthetic on the respiratory mucosa and reducing airway irritation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Libexin® TARGET Libexin® Dompé Farmaceutici S.p.A phase 3 Non-narcotic antitussive
Tessalon benzonatate Generic (originally Pfizer) marketed Non-narcotic Antitussive [EPC] Sodium channel protein type 5 subunit alpha 1958-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-narcotic antitussive class)

  1. Dompé Farmaceutici S.p.A · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Libexin® — Competitive Intelligence Brief. https://druglandscape.com/ci/libexin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: